Key result
Plasma Lp(a) levels show no significant association with incident CVD in type 2 diabetes.
Why the study?
The effect of Lp(a) on cardiovascular disease risk among diabetic patients and its difference from the general population was unclear.
Do higher plasma lipoprotein(a) levels and associated genetic variants increase the risk of cardiovascular disease in patients with type 2 diabetes?
Cohort (n=2,308)
Yes
Do higher plasma lipoprotein(a) levels and associated genetic variants increase the risk of cardiovascular disease in patients with type 2 diabetes?
Relative Risk: 1.05 (95% CI 0.96–1.15)
In patients with type 2 diabetes, plasma Lp(a) levels and associated genetic variants do not appear to significantly increase the risk of cardiovascular disease, suggesting diabetes status may attenuate this relationship.
Lp(a) may not predict CV risk in T2D; leaves open whether diabetes modifies Lp(a) effects pending dedicated trials.
AIMS: To examine the relations between genetic loci, plasma lipoprotein(a) [Lp(a)] levels, and cardiovascular disease (CVD) risk among diabetic patients and compare with the observations in the general population. METHODS AND RESULTS: In two prospective cohorts of patients with type 2 diabetes (n= 2308) from the Nurses' Health Study and the Health Professional Follow-Up Study, we performed (i) genome-wide association (GWA) scans for plasma Lp(a); (ii) prospective analysis of plasma Lp(a) for CVD risk and mortality; and (iii) genetic association analysis for CVD risk and mortality. Meta-analysis of the two GWA scans yielded 71 single-nucleotide polymorphisms (SNPs) on chromosome 6q associated with plasma Lp(a) levels at a genome-wide significance level (P< 5 × 10(-8)). The SNP rs10455872 in LPA was most strongly associated with Lp(a) (P= 4.60 × 10(-39)). Forward-selection analysis indicated that rs10455872 and other five SNPs in a region encompassing LPA, PLG, SLC22A3, and LPAL2 genes were independently associated with Lp(a) levels and jointly explained ∼20% of variation in diabetic patients. In prospective analysis, we did not find any significant association between plasma levels and CVD incidence; the relative risk for coronary heart disease (CHD), CVD, and CVD death was 1.05 [95% confidence interval (CI): 0.95-1.15], 1.05 (0.96-1.15), and 1.21 (0.99-1.47) per 1-SD higher log-transformed Lp(a) levels, respectively. Consistently, none of the Lp(a) SNPs were associated with CVD risk or mortality (all P> 0.09). For the best SNP rs10455872 for plasma Lp(a) levels, the OR for CHD, CVD, and CVD death was 0.94 (95% CI: 0.69-1.28), 0.97 (0.72-1.29), and 1.23 (0.79-1.92), respectively. The genetic effect on CHD risk showed a significant heterogeneity between the diabetic and the general populations (P= 0.006). CONCLUSION: Our data indicate that the effect of Lp(a) on CVD risk among diabetic patients might be different from that in the general population. Diabetes status may attenuate the relation between Lp(a) and cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2011) conducted a cohort in Type 2 diabetes (n=2,308). Plasma lipoprotein(a) levels and genetic variants vs. Lower plasma lipoprotein(a) levels was evaluated on Cardiovascular disease (CVD) incidence (RR 1.05, 95% CI 0.96-1.15). Plasma Lp(a) levels were not significantly associated with cardiovascular disease incidence in patients with type 2 diabetes (RR 1.05; 95% CI 0.96-1.15 per 1-SD higher log-transformed Lp(a)).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: